BioPharma Dive September 23, 2021
Dive Brief:
- AstraZeneca is putting money into a recently launched university spinoff that aims to turn RNA into self-reproducing medicines, announcing Thursday a long-term partnership with U.K.-based VaxEquity.
- Founded last year by Imperial College London and venture backer Morningside, VaxEquity is developing technology similar to the messenger RNA platform that’s been used to great success by Moderna and BioNTech, but with a key twist. Rather than use mRNA, VaxEquity is focusing on self-amplifying RNA, which it claims could allow for lower or less-frequent dosing of drugs and vaccines.
- Under the companies’ collaboration, AstraZeneca will make an undisclosed investment into VaxEquity as well as support it with research and development funding. The British pharma has an option to work...
Today's Sponsors
Today's Sponsor